Skip to main content

Antitrust, Commercial, and Administrative Law

August 18, 2017
Washington, D.C. – Following a letter sent by House Judiciary Committee Chairman Bob Goodlatte (R-Va.), House Financial Services Committee Chairman Jeb Hensarling (R-Texas), Regulatory Reform, Commercial and Antitrust Law Subcommittee Chairman Tom Marino (R-Pa.), Financial Institutions and Consumer Credit Subcommittee Chairman Blaine Luetkemeyer (R-Mo.), and Courts, Intellectual Property and the Internet Subcommittee Chairman Darrell Is
August 10, 2017
Washington, D.C. – House Judiciary Committee Chairman Bob Goodlatte (R-Va.), House Financial Services Committee Chairman Jeb Hensarling (R-Tx.), Regulatory Reform, Commercial and Antitrust Law Subcommittee Chairman Tom Marino (R-Pa.), Financial Institutions and Consumer Credit Subcommittee Chairman Blaine Luetkemeyer (R-Mo.), and Courts, Intellectual Property & the Internet Subcommittee Chairman Darrell Issa (R-Ca.) sent a letter to Attorney General Jeff Sessions, Federal Reserve Board Chair Janet Yellen, and Acting Comptroller Keith Noreika regarding Operation Choke Point
July 28, 2017
Washington, D.C. - This week, leaders of both the Senate and House Judiciary Committees called on the Justice Department and Federal Trade Commission to work with the U.S. Trade Representative to make strong competition provisions a central part of upcoming trade negotiations.
July 27, 2017
Chairman Goodlatte: The United States has been and continues to be a champion of free and open markets. An open marketplace cultivates competition among sellers and is the very foundation of maintaining lower prices, higher quality products and services, and superior innovation.
July 26, 2017
Washington, D.C. -- On Thursday, July 27, 2017 at 1:00 p.m., the Regulatory Reform, Commercial and Antitrust Law Subcommittee will hold a hearing to examine antitrust concerns with the Food and Drug Administration processes to approve new drugs. This hearing will continue the Subcommittee’s investigation of competition in the healthcare sector and will explore potential antitrust concerns with the FDA’s Risk Evaluation and Mitigation Strategy (REMS), citizen petitions, the
July 25, 2017
Washington, D.C. – House Judiciary Committee Chairman Bob Goodlatte (R-Va.) today delivered the following remarks during the Regulatory Reform, Commercial and Antitrust Law Subcommittee’s hearing on “No Regulation Without Representation:  H.R.
July 21, 2017
Washington, D.C. -- On Tuesday, July 25, 2017 at 10:00 a.m., the Subcommittee on Regulatory Reform, Commercial and Antitrust Law Subcommittee will hold a hearing on the growing problem of states imposing regulatory burdens on out-of-state businesses and the No Regulation without Representation Act of 2017 (H.R.
July 20, 2017
Washington, D.C. -- Today regulatory experts from across the country sent a letter to Senate Majority Leader Mitch McConnell (R-KY) and Minority Leader Chuck Schumer (D-NY) urging them to enact comprehensive regulatory reform.
Date:
Location:
2141 RAYBURN HOUSE OFFICE BUILDING